Metformina + Vildagliptina Krka

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Krka, is a biguanide/DPP‑4 inhibitor combination presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when used as part of a comprehensive diabetes care plan.

GNH USA supplies Metformina + Vildagliptina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring EU‑grade quality and reliable global logistics.

Metformina + Vildagliptina is used in the treatment of type 2 diabetes mellitus and related oral‑therapy strategies.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Patients inadequately controlled on metformin alone: adds DPP‑4 inhibition to improve overall glycemic control. - Adults requiring combination oral therapy: offers a single‑pill regimen to simplify treatment.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, usually transient. - Headache: mild tension‑type headache. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylactic reactions: rare systemic allergic response.

Metformina + Vildagliptina should be used with caution and appropriate monitoring. - Renal function assessment: evaluate creatinine clearance before initiation and periodically. - Hepatic function monitoring: check liver enzymes in patients with liver disease. - Risk of lactic acidosis: avoid in severe renal impairment or acute heart failure. - Concomitant hypoglycaemic agents: adjust dose of insulin or sulfonylureas to prevent low blood sugar. - Pregnancy and lactation: use only if potential benefit justifies potential risk; consult a physician. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina + Vildagliptina may interact with several medicines.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycaemia. - IV contrast agents: may precipitate renal impairment affecting metformin clearance. - Cimetidine: can raise metformin plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vildagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal function and metformin elimination. - ACE inhibitors or ARBs: monitor renal function and serum potassium. - Beta‑blockers: may mask symptoms of hypoglycaemia.